C3G

Apellis Pharmaceuticals, a global biopharmaceutical leader, has closed 2024 with robust financial results, reporting $709 million in U.S. net product revenues. This impressive performance reflects the success of SYFOVRE®, its groundbreaking treatment for geographic atrophy (GA), which generated $611 million…